Amgen (AMGN) Cash from Financing Activities (2009 - 2026)

Amgen has reported Cash from Financing Activities for 18 years, with the latest figure at -$1.5 billion in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 44.56% year-over-year to -$1.5 billion in Q2 2026; TTM through Jun 2026 was -$4.1 billion, a 65.15% increase from a year earlier, with the FY2025 full-year figure at -$10.9 billion, down 15.34% from the prior year.
• Cash from Financing Activities was -$1.5 billion for Q2 2026 at Amgen, down from $1.4 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $21.5 billion in Q1 2023, with the low at -$4.1 billion in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$183.8 million, with a median of -$1.4 billion recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 712.09% in 2023 against a maximum downside of 226.26% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$1.0 billion in 2022, then surged by 362.54% to $2.8 billion in 2023, then slumped by 151.09% to -$1.4 billion in 2024, then increased by 12.86% to -$1.2 billion in 2025, then retreated by 20.88% to -$1.5 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$1.5 billion (Q2 2026), $1.4 billion (Q1 2026), and -$1.2 billion (Q4 2025), per Business Quant data.